Vyome Holdings, Inc. (NASDAQ:HIND) Receives $15.00 Consensus PT from Analysts

Vyome Holdings, Inc. (NASDAQ:HIND) has been given a consensus recommendation of “Hold” by the five research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $15.00.

A number of equities analysts have weighed in on the company. Zacks Research raised Vyome to a “hold” rating in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vyome in a report on Wednesday, July 29th. Finally, Litchfield Hills Research assumed coverage on Vyome in a report on Monday, May 4th. They set a “buy” rating on the stock.

Hedge Funds Weigh In On Vyome

An institutional investor recently bought a new position in Vyome stock. Geode Capital Management LLC bought a new stake in Vyome Holdings, Inc. (NASDAQ:HIND) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned about 0.21% of Vyome at the end of the most recent reporting period. 22.06% of the stock is owned by institutional investors.

Vyome Trading Down 1.3%

HIND stock opened at $2.25 on Friday. The company has a market cap of $15.79 million, a price-to-earnings ratio of -0.67 and a beta of 1.48. Vyome has a 12 month low of $1.75 and a 12 month high of $12.00. The firm has a 50-day moving average of $2.18 and a two-hundred day moving average of $2.29.

Vyome (NASDAQ:HIND) last released its earnings results on Wednesday, August 12th. The company reported ($0.10) earnings per share for the quarter. The business had revenue of $0.27 million during the quarter. Vyome had a negative return on equity of 197.33% and a negative net margin of 3,024.84%. As a group, equities analysts forecast that Vyome will post -0.6 earnings per share for the current year.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.